https://www.corxelbio.com/en/ 2026-04-21T16:13:26+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/ 2025-05-27T17:36:00+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/roderick-wong-md/ 2024-10-23T10:04:37+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/peter-fong-phd/ 2025-01-13T14:41:49+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/sandy-mou-md/ 2025-04-14T16:49:59+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/kevin-xie-phd/ 2025-04-14T16:49:53+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/bo-liang-md-phd/ 2026-01-29T09:00:44+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/rainy-zhou/ 2025-04-15T17:14:13+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/christine-dai/ 2025-04-15T17:14:18+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/john-li/ 2025-04-14T16:49:07+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/michele-park-phd/ 2026-02-03T13:55:20+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/chen-yu-md/ 2026-02-03T13:29:22+00:00 https://www.corxelbio.com/en/corxel-pharmaceuticals/amit-shah-md/ 2026-02-03T13:34:40+00:00 https://www.corxelbio.com/en/pipeline-science/ 2026-04-21T16:36:14+00:00 https://www.corxelbio.com/en/pipeline-science/obesity/ 2025-11-27T17:31:44+00:00 https://www.corxelbio.com/en/pipeline-science/type-2-diabetes-mellitus-t2dm/ 2025-11-27T17:26:50+00:00 https://www.corxelbio.com/en/pipeline-science/acute-ischemic-stroke-ais/ 2026-03-10T15:00:20+00:00 https://www.corxelbio.com/en/pipeline-science/presbyopia/ 2025-11-28T10:44:22+00:00 https://www.corxelbio.com/en/our-expertise/ 2025-04-29T17:06:09+00:00 https://www.corxelbio.com/en/our-expertise/our-strategic-partners/ 2024-09-11T16:18:13+00:00 https://www.corxelbio.com/en/our-expertise/global-opportunities/ 2025-01-13T13:33:39+00:00 https://www.corxelbio.com/en/join-us/ 2026-04-23T09:46:11+00:00 https://www.corxelbio.com/en/press-releases/ 2024-11-21T10:59:55+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-and-jixing-announce-expansion-of-collaboration-to-include-licensing-of-omecamtiv-mecarbil-in-china-rtw-to-add-to-its-investment-in-cytokinetics/ 2022-03-04T09:22:08+00:00 https://www.corxelbio.com/en/press-releases/jixing-completes-phase-1-study-of-aficamten-a-potential-next-generation-cardiac-myosin-inhibitor-for-patients-with-hypertrophic-cardiomyopathy-hcm/ 2022-04-18T07:22:56+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-ind-approval-for-phase-1-and-phase-3-clinical-trials-of-etripamil-in-patients-with-paroxysmal-supraventricular-tachycardia-psvt-in-china/ 2022-03-04T08:14:30+00:00 https://www.corxelbio.com/en/press-releases/oyster-point-pharma-announces-exclusive-license-agreement-with-jixing-pharmaceuticals-to-develop-and-commercialize-oc-01-and-oc-02-in-greater-china/ 2022-03-04T08:46:29+00:00 https://www.corxelbio.com/en/press-releases/rtw-investments-backed-jixing-pharmaceuticals-appoints-joseph-romanelli-chief-executive-officer/ 2022-12-05T10:34:17+00:00 https://www.corxelbio.com/en/press-releases/milestone-pharmaceuticals-announces-exclusive-license-agreement-with-jixing-pharmaceuticals-to-develop-and-commercialize-etripamil-for-psvt-in-greater-china/ 2022-03-04T08:08:44+00:00 https://www.corxelbio.com/en/press-releases/rtw-investments-lp-jixing-pharmaceuticals-and-cytokinetics-enter-into-strategic-financing-collaboration-to-support-the-development-of-ck-274-and-enter-china/ 2022-03-29T08:37:21+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-announces-fda-acceptance-of-new-drug-application-for-omecamtiv-mecarbil-for-the-treatment-of-heart-failure-with-reduced-ejection-fraction/ 2022-03-29T09:01:52+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-receipt-of-breakthrough-therapy-designation-for-aficamten-in-china/ 2022-04-18T07:10:45+00:00 https://www.corxelbio.com/en/press-releases/jixing-presents-results-of-china-phase-i-study-of-aficamten-at-the-2022-american-society-for-clinical-pharmacology-and-therapeutics-annual-meeting/ 2022-04-18T07:11:48+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-receipt-of-clinical-trial-application-approval-for-oc-01-nasal-spray-phase-3-trial-for-the-treatment-of-signs-and-symptoms-of-dry-eye-diseases-in-china/ 2022-04-18T07:10:13+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-appointment-of-kun-wu-as-the-chief-commercial-officer/ 2022-04-18T07:21:09+00:00 https://www.corxelbio.com/en/press-releases/lenz-therapeutics-and-jixing-announce-an-exclusive-greater-china-license-agreement-rtw-to-invest-in-lenz-therapeutics/ 2022-04-18T07:08:46+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-leadership-transition/ 2022-04-28T02:45:52+00:00 https://www.corxelbio.com/en/press-releases/hovione-and-jixing-announce-an-exclusive-global-license-agreement-for-ophthalmology-program/ 2022-05-09T03:15:50+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-receipt-of-clinical-trial-application-approval-for-china-cohort-of-phase-3-clinical-trial-of-aficamten/ 2022-06-29T07:42:10+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-first-patient-enrollment-in-phase-3-study-of-etripamil-in-china/ 2022-07-01T09:13:15+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-first-patients-enrolled-in-phase-3-clinical-study-of-oc-01-nasal-spray-in-china/ 2022-07-22T06:22:09+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-first-patient-enrolled-in-china-cohort-of-phase-3-clinical-trial-of-aficamten/ 2022-08-26T03:25:44+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-grand-opening-of-the-new-headquarter-office-in-china/ 2022-09-08T09:04:24+00:00 https://www.corxelbio.com/en/press-releases/milestone-pharmaceuticals-announces-positive-results-from-phase-3-rapid-clinical-trial-of-etripamil-nasal-spray-in-patients-with-paroxysmal-supraventricular-tachycardia/ 2023-02-27T10:10:33+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-nmpa-acceptance-of-new-drug-application-submission-for-omecamtiv-mecarbil/ 2022-11-07T09:00:05+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-appointment-of-sandy-mou-as-chief-executive-officer/ 2023-02-27T10:19:08+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-acquisition-of-an-innovative-cardiovascular-asset-for-global-development/ 2023-02-27T10:15:09+00:00 https://www.corxelbio.com/en/press-releases/jixing-presents-the-latest-research-data-of-cardiovascular-asset-jx09-at-the-american-college-of-cardiology-annual-congress-2023/ 2023-05-22T10:32:47+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-presents-positive-results-from-cohort-4-of-redwood-hcm-and-long-term-results-from-forest-hcm-at-the-american-college-of-cardiology-72nd-annual-scientific-session/ 2023-05-23T10:34:44+00:00 https://www.corxelbio.com/en/press-releases/jixing-ophthalmology-product-varenicline-solution-nasal-spray-is-available-at-boao-super-hospital-in-hainan-province/ 2023-04-06T09:26:17+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-presents-new-data-in-patients-with-non-obstructive-hcm-from-cohort-4-of-redwood-hcm-in-late-breaking-clinical-trial-session-at-the-european-society-of-cardiology-heart-failure-2023-congress/ 2023-05-23T10:34:09+00:00 https://www.corxelbio.com/en/press-releases/milestone-pharmaceuticals-announces-presentation-of-data-from-analysis-of-etripamil-nasal-spray-in-patients-experiencing-atrial-fibrillation-with-rapid-ventricular-rate/ 2023-05-25T09:21:04+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-completion-of-patient-enrollment-in-china-cohort-of-phase-3-clinical-trial-sequoia-hcm-of-aficamten/ 2023-06-05T11:56:26+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-announces-start-of-maple-hcm-a-phase-3-clinical-trial-of-aficamten-compared-to-metoprolol-in-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy/ 2023-07-11T16:30:15+00:00 https://www.corxelbio.com/en/press-releases/jixing-and-tsh-biopharm-announce-strategic-partnership-agreement/ 2023-07-12T10:38:36+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-nmpa-acceptance-of-new-drug-application-for-varenicline-solution-nasal-spray/ 2023-08-22T14:16:25+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-positive-topline-results-from-china-phase-3-study-for-ophthalmology-product-varenicline-solution-nasal-spray/ 2023-08-22T14:14:49+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-acceptance-of-the-clinical-trial-application-for-the-phase-3-clinical-trial-of-aficamten-compared-to-metoprolol-in-patients-with-symptomatic-obstructive-hypertrophic-cardiomyopathy-by-the-national-medical-products-admin/ 2023-10-24T14:01:08+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-approval-of-the-clinical-trial-application-for-the-phase-3-clinical-trial-of-lnz100-and-lnz101-for-the-treatment-of-presbyopia-in-china/ 2023-08-22T14:09:40+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-first-patient-enrolled-in-phase-3-clinical-study-of-lnz100-and-lnz101-for-the-treatment-of-presbyopia-in-china/ 2024-01-10T10:31:33+00:00 https://www.corxelbio.com/en/press-releases/jixing-and-wuzhou-announce-distribution-agreement/ 2023-09-29T18:18:38+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-presents-baseline-characteristics-from-sequoia-hcm-at-the-hcm-society-scientific-sessions/ 2023-10-13T10:28:57+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-announces-start-of-acacia-hcm-a-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-symptomatic-non-obstructive-hypertrophic-cardiomyopathy/ 2023-10-11T10:05:30+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-national-medical-products-administration-approval-of-the-clinical-trial-application-for-the-china-cohort-of-maple-hcm-the-phase-3-clinical-trial-of-aficamten-compared-to-metoprolol-in-patients-with-symptomatic-obstructive-h/ 2023-10-24T13:58:52+00:00 https://www.corxelbio.com/en/press-releases/milestone-pharmaceuticals-announces-submission-of-new-drug-application-to-the-us-fda-for-etripamil/ 2023-10-26T15:17:36+00:00 https://www.corxelbio.com/en/press-releases/jixing-and-wuxi-sta-announce-strategic-partnership-agreement/ 2024-01-09T15:43:19+00:00 https://www.corxelbio.com/en/press-releases/milestone-pharmaceuticals-presents-positive-results-from-revera-phase-2-study-of-etripamil-in-afib-rvr-at-the-american-heart-association-scientific-sessions-2023/ 2023-11-20T14:11:56+00:00 https://www.corxelbio.com/en/press-releases/jixing-s-milestone-the-university-of-hong-kong-shenzhen-hospital-issued-the-first-prescription-for-varenicline-solution-nasal-spray/ 2023-12-13T15:18:39+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-announces-positive-results-from-sequoia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-obstructive-hypertrophic-cardiomyopathy/ 2024-05-13T12:00:53+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-positive-results-from-the-china-cohort-of-sequoia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-obstructive-hypertrophic-cardiomyopathy/ 2024-01-03T14:10:16+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-tfda-acceptance-of-new-drug-application-for-varenicline-solution-nasal-spray-for-the-taiwan-region/ 2024-01-03T16:41:56+00:00 https://www.corxelbio.com/en/press-releases/bayer-and-rtw-investments-lead-series-d-financing-in-chinese-biotech-ji-xing-pharmaceuticals/ 2024-01-09T15:44:17+00:00 https://www.corxelbio.com/en/press-releases/jixing-acquires-biib131-from-biogen-to-treat-acute-ischemic-stroke/ 2024-01-11T17:48:08+00:00 https://www.corxelbio.com/en/press-releases/tms-and-jixing-announce-a-series-of-strategic-collaborations/ 2024-01-11T17:28:02+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-first-subject-successfully-dosed-in-australian-phase-i-clinical-trial-of-jx09/ 2024-02-20T10:39:29+00:00 https://www.corxelbio.com/en/press-releases/the-phase-3-study-results-of-varenicline-solution-nasal-spray-for-the-treatment-of-dry-eye-disease-in-chinese-patients-was-published-in-the-lancet-subset/ 2024-03-08T18:25:41+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-cta-approval-of-china-cohort-of-acacia-hcm-a-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-symptomatic-non-obstructive-hypertrophic-cardiomyopathy/ 2024-03-13T10:34:27+00:00 https://www.corxelbio.com/en/press-releases/lenz-therapeutics-announces-positive-topline-data-from-phase-3-clarity-presbyopia-trials/ 2024-04-07T13:11:08+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-presents-additional-48-week-data-from-forest-hcm-the-open-label-extension-clinical-study-of-aficamten-at-the-american-college-of-cardiology-73ʳᵈ-annual-scientific-session/ 2024-04-08T10:09:18+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-announces-primary-results-from-sequoia-hcm-presented-in-late-breaking-clinical-trial-session-at-the-european-society-of-cardiology-heart-failure-2024-congress-and-published-in-the-new-england-journal-of-medicine/ 2024-05-15T15:29:35+00:00 https://www.corxelbio.com/en/press-releases/lenz-therapeutics-announces-submission-of-new-drug-application-to-us-food-and-drug-administration-for-lnz100-for-the-treatment-of-presbyopia/ 2024-08-14T11:23:30+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-the-successful-completion-of-patient-enrollment-in-phase-3-clinical-study-of-lnz100-for-the-treatment-of-presbyopia-in-china/ 2024-08-19T14:33:20+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-presents-new-data-related-to-the-safety-and-long-term-use-of-aficamten-at-the-european-society-of-cardiology-congress-2024/ 2024-09-09T20:16:44+00:00 https://www.corxelbio.com/en/press-releases/jixing-announces-positive-results-from-phase-3-jx02002-clinical-trial-of-etripamil-nasal-spray-in-patients-with-paroxysmal-supraventricular-tachycardia/ 2024-09-09T20:15:35+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-nmpa-acceptance-of-new-drug-application-for-aficamten/ 2024-10-18T09:44:26+00:00 https://www.corxelbio.com/en/press-releases/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3-presbyopia-trial-of-lnz100/ 2024-10-28T10:11:08+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-tfda-approval-of-new-drug-application-for-varenicline-solution-nasal-spray-for-the-taiwan-region/ 2024-11-23T09:24:14+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-nmpa-approval-of-new-drug-application-for-varenicline-solution-nasal-spray/ 2024-11-29T11:11:55+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-nmpa-acceptance-of-priority-review-for-aficamten/ 2024-12-05T13:38:44+00:00 https://www.corxelbio.com/en/press-releases/cytokinetics-announces-fda-acceptance-of-new-drug-application-for-aficamten-for-the-treatment-of-obstructive-hypertrophic-cardiomyopathy/ 2025-03-27T16:23:09+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-strategic-collaboration-agreement-with-grand-pharma/ 2024-12-11T18:44:08+00:00 https://www.corxelbio.com/en/press-releases/corxel-and-sanofi-announce-an-agreement-for-aficamten-in-greater-china-markets/ 2024-12-20T13:02:07+00:00 https://www.corxelbio.com/en/press-releases/corxel-acquires-worldwide-excluding-greater-china-rights-to-an-oral-small-molecule-glp-1-ra-for-the-treatment-of-obesity-and-diabetes/ 2024-12-23T21:01:12+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-nmpa-acceptance-of-new-drug-application-for-etripamil/ 2025-03-27T16:27:28+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-upcoming-presentation-at-the-international-stroke-conference-2025-on-jx10-improving-neurological-outcomes-in-acute-lacunar-infarct/ 2025-01-23T10:58:04+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-china-national-medical-products-administration-approval-of-the-clinical-trial-application-for-orion-the-global-registrational-study-of-jx10-in-patients-with-acute-ischemic-stroke/ 2025-03-27T16:12:50+00:00 https://www.corxelbio.com/en/press-releases/corxel-bolsters-leadership-team-with-seasoned-cfo-kevin-xie-to-drive-next-phase-of-company-growth/ 2025-03-27T16:12:06+00:00 https://www.corxelbio.com/en/press-releases/corxel-receives-study-may-proceed-letter-from-the-us-fda-for-the-phase-2-trial-of-cx11-in-patients-with-obesity-and-overweight-conditions/ 2025-04-15T11:00:15+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-first-patient-enrolled-in-orion-the-registrational-clinical-trial-of-jx10-in-patients-with-acute-ischemic-stroke/ 2025-05-16T11:46:48+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-first-patient-enrolled-in-the-us-phase-2-trial-of-cx11-in-obese-and-overweight-patients/ 2025-06-18T10:14:06+00:00 https://www.corxelbio.com/en/press-releases/data-from-the-phase-2-clinical-trial-of-cx11vct220-in-china-presented-at-ada-2025/ 2025-06-23T11:00:40+00:00 https://www.corxelbio.com/en/press-releases/corxel-receives-study-may-proceed-letter-from-the-us-fda-for-the-phase-2-trial-of-cx11-in-patients-with-type-2-diabetes-mellitus/ 2026-01-19T09:33:42+00:00 https://www.corxelbio.com/en/press-releases/milestone-receives-fda-approval-of-cardamyst-etripamil-as-first-and-only-self-administered-nasal-spray-for-adults-with-paroxysmal-supraventricular-tachycardia-psvt/ 2026-01-19T09:43:36+00:00 https://www.corxelbio.com/en/press-releases/corxel-announces-287-million-series-d1-financing-to-further-advance-its-cardiometabolic-pipeline-including-oral-small-molecule-glp-1-receptor-agonist/ 2026-01-23T08:16:00+00:00 https://www.corxelbio.com/en/press-releases/corxel-pharmaceuticals-enters-into-asset-purchase-agreement-with-everest-medicines-for-the-development-and-commercialization-of-cardamyst-etripamil-nasal-spray-in-greater-china-by-everest-medicines/ 2026-03-23T10:38:22+00:00 https://www.corxelbio.com/en/press-releases/vincentage-pharma-reports-positive-top-line-results-from-pivotal-phase-3-trial-of-vct220-in-obese-or-overweight-chinese-adults/ 2026-05-18T18:16:41+00:00 https://www.corxelbio.com/en/contact/ 2026-04-13T13:13:17+00:00 https://www.corxelbio.com/en/terms-of-use/ 2025-03-11T15:53:59+00:00 https://www.corxelbio.com/en/privacy-notice/ 2026-04-17T19:31:53+00:00 https://www.corxelbio.com/en/settings/ 2025-11-28T10:53:15+00:00 https://www.corxelbio.com/en/privacy-notice-for-clinical-trial-participants/ 2025-12-26T13:43:25+00:00 https://www.corxelbio.com/en/privacy-notice-for-clinical-trial-personnel/ 2025-12-26T13:44:35+00:00